Quarterly report
Open the filing on sec.gov
IGC Pharma, Inc. (IGC)
NYSE: IGC · Pharmaceutical Preparations · Potomac, MD · filing with the SEC since 2005
The companyfiscal 2025, as filed
Revenue$1.3M-5.5%
Net income-$7.1M+45.2%
Earnings per share$-0.09+59.1%
Operating cash flow-$4.8M+7.8%
Cash$405,000-66.2%
Debt$134,000-2.2%
Shareholders’ equity$6.3M-13.5%
Shares, diluted76.5M+30.0%
Return on equityn/a
The recordfrom its filings
Filings in 202625
Newest filingNov 6 · 10-Q
Annual reportMar 18, 2026
Quarterly reportNov 6, 2026
Next report due10-KT by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted7
Filer categoryNon-accelerated filer<br>Smaller reporting company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Extra proxy material
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.